索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]裴华楠,邵群,张玲霞,等.免疫检查点抑制剂相关心肌炎的诊治进展[J].国际心血管病杂志,2022,04:210-215.
点击复制

免疫检查点抑制剂相关心肌炎的诊治进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2022年04期
页码:
210-215
栏目:
综述
出版日期:
2022-08-30

文章信息/Info

Title:
-
作者:
裴华楠; 邵群; 张玲霞; 张志仁
150000 哈尔滨医科大学附属肿瘤医院心内科
Author(s):
-
关键词:
免疫检查点抑制剂; 心肌炎; 免疫不良反应
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2022.04.006
文献标识码:
-
摘要:
免疫检查点抑制剂（ICIs）在临床中的应用日益增多，在取得良好疗效的同时， 也应注意其产生的不良反应。ICIs 相关心肌炎是ICIs 类药物较严重的不良反应。其临床表 现不具有特异性，且容易呈暴发性进展。该文介绍ICIs 相关心肌炎的发病机制、临床特点、 诊断以及治疗进展。
Abstract:
-

参考文献/References

[1] Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4):iv264-iv266.
[2] Calabretta R, Hoeller C, Pichler V, et al. Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries[J]. Circulation, 2020, 142(24):2396-2398.
[3] 赵一贺, 王虹剑, 宋卫华. 免疫检查点抑制剂相关心脏毒性 的研究进展[J]. 中国循环杂志, 2020, 35(5):518-520.
[4] 蒙秋华, 田婧, 覃斐, 等. PD-1、PD-L1通路抑制剂在消化系 统肿瘤免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(8):942-994.
[5] Zhang L, Reynolds KL, Lyon AR, et al. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity[J]. JACC CardioOncol, 2021, 3(1):35-47.
[6] Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2):158-168.
[7] Sury K, Perazella MA, Shirali AC. Cardiorenal complications of immune checkpoint inhibitors[J]. Nat Rev Nephrol, 2018, 14(9):571-588.
[8] Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018, 36(17):1714-1768.
[9] Altan M, Toki M, Gettinger SN, et al. Immune checkpoint inhibitor-associated pericarditis[J]. J Thorac Oncol, 2019, 14(6):1102-1108.
[10] Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J, 2013, 34(33):2636-2648.
[11] Lyon AR, Yousaf N, Battisti N, et al. Immune checkpoint inhibitors and cardiovascular toxicity[J]. Lancet Oncol, 2018, 19(9):e447-e458.
[12] Norwood TG, Westbrook BC, Johnson DB, et al. Smoldering myocarditis following immune checkpoint blockade[J]. J Immunother Cancer, 2017, 5(1):91-96.
[13] Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors[J]. J Am Coll Cardiol, 2018, 71(16):1755-1764.
[14] Ederhy S, Voisin AL, Champiat S. Myocarditis with immune checkpoint blockade[J]. N Engl J Med, 2017, 376(3):290-291.
[15] Bando S, Soeki T, Matsuura T, et al. Plasma brain natriuretic peptide levels are elevated in patients with cancer[J]. PLoS One, 2017, 12(6):e0178607.
[16] Jain V, Bahia J, Mohebtash M, et al. Cardiovascular c o m p l i c a t i o n s a s s o c i a t e d w i t h n o v e l c a n c e r immunotherapies[J]. Curr Treat Options Cardiovasc Med, 2017, 19(5):36.
[17] Guo X, Wang H, Zhou J, et al. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity[J]. Thorac Cancer, 2020, 11(2):475-480.
[18] Zlotoff DA, Hassan M, Zafar A, et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis[J]. J Immunother Cancer, 2021, 9(3):e002007.
[19] Zhang L, Awadalla M, Mahmood SS, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis[J]. Eur Heart J, 2020, 41(18):1733-1743.
[20] Awadalla M, Mahmood SS, Groarke JD, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis[J]. J Am Coll Cardiol, 2020, 75(5):467-478.
[21] Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment[J]. J Am Heart Assoc, 2020, 9(2):e013757.
[22] Asnani A. Cardiotoxicity of immunotherapy: incidence, diagnosis, and management[J]. Curr Oncol Rep, 2018, 20(6):44.
[23] Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3):230-241.
[24] 中国抗癌协会整合肿瘤心脏病学分会, 中华医学会心血管 病学分会肿瘤心脏病学学组, 中国医师协会心血管内科医 师分会肿瘤心脏病学专业委员会, 等. 免疫检查点抑制剂相 关心肌炎监测与管理中国专家共识(2020版)[J]. 中国肿瘤 临床, 2020, 47(20):1027-1038.
[25] Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017, 5(1):95-122.
[26] Bonaca MP, Olenchock B, Salem JE, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology[J]. Circulation, 2019, 140(2):80-91.
[27] Zhang L, Zlotoff DA, Awadalla M, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis[J]. Circulation, 2020, 141(24):2031-2034.
[28] Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241.
[29] Agrawal N, Khunger A, Vachhani P, et al. Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature[J]. Case Rep Oncol, 2019, 12(1):260- 276.
[30] Frigeri M, Meyer P, Banfi C, et al. Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists[J]. Can J Cardiol, 2018, 34(1):92.e1-92.e3.
[31] Cautela J, Zeriouh S, Gaubert M, et al. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis[J]. J Immunother Cancer, 2020, 8(2):e001887.
[32] Verheijden RJ, May AM, Blank CU, et al. Association of anti- TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch Melanoma Treatment Registry[J]. Clin Cancer Res, 2020, 26(9): 2268- 2274.
[33] Tay RY, Blackley E, Mclean C, et al. Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy[J]. Br J Cancer, 2017, 117(7):921-924.
[34] Cahoon WD, Ensor CR, Shullo MA. Alemtuzumab for cytolytic induction of immunosuppression in heart transplant recipients[J]. Prog Transplant, 2012, 22(4):344-350.
[35] Esfahani K, Buhlaiga N, Thébault P, et al. Alemtuzumab for immune-related myocarditis due to PD-1 therapy[J]. N Engl J Med, 2019, 380(24):2375-2376.
[36] Zhou YW, Zhu YJ, Wang MN, et al. Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism, diagnosis and management[J]. Front Pharmacol, 2019, 10:1350.
[37] Salem JE, Allenbach Y, Vozy A, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis[J]. N Engl J Med, 2019, 380(24):2377-2379.
[38] Damsky WE, Vesely MD, Lee AI, et al. Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib[J]. JAAD Case Rep, 2019, 5(12):1018- 1026.
[39] Liu Y, Jiang L. Tofacitinib for treatment in immune-mediated myocarditis: the first reported cases[J]. J Oncol Pharm Pract, 2020, Aug 11. [Online ahead of print].
[40] Li B, Jones LL, Geiger TL. IL-6 promotes T cell proliferation and expansion under inflammatory conditions in association with low-level RORγt expression[J]. J Immunol, 2018, 201(10):2934-2946.
[41] Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia[J]. Nat Rev Cardiol, 2020, 17(8):474-502.
[42] Ramesh R, Kozhaya L, Mckevitt K, et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids[J]. J Exp Med, 2014, 211(1):89- 104.
[43] Doms J, Prior JO, Peters S, et al. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis[J]. Ann Oncol, 2020, 31(9):1273-1275.
[44] Bermas BL, Zaha VG. Mending broken hearts: a new treatment paradigm for immune checkpoint inhibitor-induced myocarditis[J]. Circulation, 2021, 143(8):767-769.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（81930009）
通信作者：张志仁， E-mail: zhirenz@163.com
更新日期/Last Update: 2022-08-30